Bank of America
XLO icon

Bank of America’s Xilio Therapeutics XLO Stock Holding History

Bank of America’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19
Closed -$167 – 6936
2025
Q4 		$167 Buy
19
+1
+6% +$11 ﹤0.01% 6734
2025
Q3 		$207 Sell
18
-6
-25% -$60 ﹤0.01% 7728
2025
Q2 		$225 Buy
24
+3
+14% +$32 ﹤0.01% 7820
2025
Q1 		$210 Buy
21
+2
+11% +$25 ﹤0.01% 7679
2024
Q4 		$253 Hold
19
– – ﹤0.01% 7542
2024
Q3 		$209 Sell
19
-30
-61% -$368 ﹤0.01% 7557
2024
Q2 		$656 Buy
+49
New +$767 ﹤0.01% 7301
2024
Q1 		– Sell
-1
Closed -$6 – 8244
2023
Q4 		$6 Sell
1
-16,193
-100% -$320K ﹤0.01% 7843
2023
Q3 		$478K Sell
16,194
-35
-0.2% -$1.31K ﹤0.01% 5342
2023
Q2 		$595K Sell
16,229
-5
-0% -$213 ﹤0.01% 5159
2023
Q1 		$720K Sell
16,234
-414
-2% -$18.2K ﹤0.01% 5128
2022
Q4 		$627K Buy
+16,648
New +$562K ﹤0.01% 5206
2022
Q2 		– Sell
-187
Closed -$19K – 8434
2022
Q1 		$19K Sell
187
-154
-45% -$24.4K ﹤0.01% 7540
2021
Q4 		$76K Buy
+341
New +$81.3K ﹤0.01% 7012

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America's XLO Position: Q1 2026 in Review

Bank of America sold out of Xilio Therapeutics (XLO) in Q1 2026, closing a stake of 19 shares — an estimated $167 sold.

Bank of America first reported a position in XLO in Q4 2021 and held it in 14 quarters. The position peaked at $720K in Q1 2023. 24 funds tracked by Wall St. Rank hold XLO as of Q1 2026.

  • Bank of America reported no remaining Xilio Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 19 Xilio Therapeutics shares in Q1 2026, an estimated $167.
  • Bank of America first reported a position in Xilio Therapeutics in Q4 2021 and held it in 14 quarters.
  • Bank of America's Xilio Therapeutics position peaked at $720K in Q1 2023.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.